His scientific interests lie mostly in Internal medicine, Cancer, Oncology, Cancer research and Pathology. His research integrates issues of Mutation, Immunology, Genetic testing and Drug resistance in his study of Cancer. His Oncology research includes themes of Chemotherapy, Genome, Targeted therapy, Carcinoma and Prospective cohort study.
His work carried out in the field of Targeted therapy brings together such families of science as Precision medicine, DNA sequencing and Genomics. The concepts of his Cancer research study are interwoven with issues in Entrectinib, Trk receptor, Mutant, AKT1 and KRAS. His Clinical trial study incorporates themes from Young adult and Overall response rate.
David M. Hyman mainly focuses on Internal medicine, Oncology, Cancer, Cancer research and Clinical trial. His study in the field of Adverse effect, Cohort, Clinical endpoint and Ovarian cancer is also linked to topics like In patient. His study looks at the intersection of Oncology and topics like Germline with Germline mutation.
He has researched Cancer in several fields, including Mutation and Bioinformatics. David M. Hyman usually deals with Cancer research and limits it to topics linked to Trk receptor and Protein kinase domain. David M. Hyman studies Pathology, namely Histiocytosis.
The scientist’s investigation covers issues in Internal medicine, Oncology, Cancer, Cancer research and Clinical trial. The Internal medicine study combines topics in areas such as Gastroenterology and PTEN. The study incorporates disciplines such as INVESTIGATIONAL AGENTS, Precision medicine, Metastatic breast cancer and Cohort in addition to Oncology.
His Cancer research is multidisciplinary, incorporating elements of Mutation, Salivary gland, Discontinuation and Confidence interval. His Cancer research research is multidisciplinary, incorporating perspectives in Trastuzumab, Mutant, Gene, Fibroblast growth factor receptor and Kinase. His Clinical trial study combines topics in areas such as Incidence, Drug development, Quality of life, Leiomyosarcoma and ATRX.
David M. Hyman spends much of his time researching Cancer research, Cancer, Internal medicine, Lineage and Trk receptor. His studies deal with areas such as Trastuzumab, Lung cancer, Pathology, Gene and Cytotoxic T cell as well as Cancer research. His Cancer research includes elements of CHEK2 and Glioma.
His Internal medicine research integrates issues from PI3K/AKT/mTOR pathway, PTEN and Oncology. His Oncology study combines topics from a wide range of disciplines, such as Cancer screening, Cohort, Medical diagnosis, Point of care and DNA sequencing. His Trk receptor research incorporates themes from Absolute neutrophil count, Young adult, Adverse effect, Genome and Clinical endpoint.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed.
Nature Medicine (2017)
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon;Theodore W. Laetsch;Shivaani Kummar;Steven G. DuBois.
The New England Journal of Medicine (2018)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman;Igor Puzanov;Vivek Subbiah;Jason E. Faris.
The New England Journal of Medicine (2015)
OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty;Jianjiong Gao;Sarah Phillips;Ritika Kundra.
JCO precision oncology (2017)
AACR project genie: Powering precision medicine through an international consortium
S. M. Sweeney;E. Cerami;A. Baras;T. J. Pugh.
Cancer Discovery (2017)
A view on drug resistance in cancer
Neil Vasan;Neil Vasan;José Baselga;José Baselga;José Baselga;David M. Hyman;David M. Hyman.
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell;Luc G. T. Morris;Claud M. Grigg;Jeffrey K. Weber.
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Pedram Razavi;Matthew T. Chang;Guotai Xu;Chaitanya Bandlamudi.
Cancer Cell (2018)
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M. Hyman;Sarina A. Piha-Paul;Helen Won;Jordi Rodon.
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L. Diamond;Lorenzo Dagna;David M. Hyman;Giulio Cavalli.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: